A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Clinical trial NCT03011372 · COMPLETED
Trial details
- NCT number
- NCT03011372
- Sponsor
- Incyte Corporation
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-25
- Primary completion
- 2024-10-30
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.